178 related articles for article (PubMed ID: 19285100)
1. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action.
Atassi MZ
Toxicon; 2009 Oct; 54(5):600-13. PubMed ID: 19285100
[TBL] [Abstract][Full Text] [Related]
2. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.
Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR
Mol Immunol; 2008 Sep; 45(15):3878-88. PubMed ID: 18676021
[TBL] [Abstract][Full Text] [Related]
4. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
[TBL] [Abstract][Full Text] [Related]
5. A peptide-based immunoassay for antibodies against botulinum neurotoxin A.
Atassi MZ; Dolimbek BZ; Deitiker P; Jankovic J; Aoki KR
J Mol Recognit; 2007; 20(1):15-21. PubMed ID: 16981247
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies.
Maruta T; Dolimbek BZ; Aoki KR; Atassi MZ
J Neurosci Methods; 2006 Mar; 151(2):90-6. PubMed ID: 16466805
[TBL] [Abstract][Full Text] [Related]
7. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin.
Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
Mol Immunol; 2008 Feb; 45(4):910-24. PubMed ID: 17897717
[TBL] [Abstract][Full Text] [Related]
8. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.
Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR
Immunobiology; 2011 Jul; 216(7):782-92. PubMed ID: 21281977
[TBL] [Abstract][Full Text] [Related]
9. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin.
Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
Immunobiology; 2011 Jun; 216(6):698-706. PubMed ID: 21183243
[TBL] [Abstract][Full Text] [Related]
10. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ
Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155
[TBL] [Abstract][Full Text] [Related]
11. Location of the synaptosome-binding regions on botulinum neurotoxin B.
Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
Biochemistry; 2012 Jan; 51(1):316-28. PubMed ID: 22146011
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions.
Atassi MZ
Toxicon; 2015 Dec; 107(Pt A):50-8. PubMed ID: 26086358
[TBL] [Abstract][Full Text] [Related]
13. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.
Atassi MZ; Oshima M
Crit Rev Immunol; 1999; 19(3):219-60. PubMed ID: 10422600
[TBL] [Abstract][Full Text] [Related]
14. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A.
Atassi MZ; Dolimbek GS; Deitiker PR; Aoki KR; Dolimbek BZ
Mol Immunol; 2005 Aug; 42(12):1509-20. PubMed ID: 15950744
[TBL] [Abstract][Full Text] [Related]
15. Basic immunological aspects of botulinum toxin therapy.
Atassi MZ
Mov Disord; 2004 Mar; 19 Suppl 8():S68-84. PubMed ID: 15027058
[TBL] [Abstract][Full Text] [Related]
16. Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.
Atassi MZ; Dolimbek BZ; Steward LE; Aoki KR
Crit Rev Immunol; 2007; 27(4):319-41. PubMed ID: 18197812
[TBL] [Abstract][Full Text] [Related]
17. Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates.
Atassi MZ; Naqvi M; Dolimbek BZ; Aoki KR
J Neuroimmunol; 2014 Jul; 272(1-2):29-34. PubMed ID: 24841626
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.
Aoki KR; Smith LA; Atassi MZ
Crit Rev Immunol; 2010; 30(2):167-87. PubMed ID: 20370628
[TBL] [Abstract][Full Text] [Related]
19. Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates.
Dolimbek BZ; Aoki KR; Atassi MZ
Immunol Lett; 2011 Jun; 137(1-2):46-52. PubMed ID: 21324340
[TBL] [Abstract][Full Text] [Related]
20. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains.
Atassi MZ; Oshima M; Dolimbek BZ; Aoki KR
Immunobiology; 2012 Jan; 217(1):1-7. PubMed ID: 22015045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
